Why the study?
International guidelines cannot be routinely applied in the Asia-Pacific region due to unique patient characteristics, heterogeneous access and resources, and low regional representation in pivotal studies.
Provides tailored consensus recommendations for antithrombotic management in high-risk chronic coronary syndrome patients specific to the Asia-Pacific region.
Answers are grounded in this paper and cite their sources.
Informs antithrombotic therapy selection balancing bleeding and ischemic risks in Asian CCS patients; extends prior guidelines with Asia-Pacific-specific consensus.
The unique characteristics of patients with chronic coronary syndrome (CCS) in the Asia-Pacific region, heterogeneous approaches because of differences in accesses and resources and low number of patients from the Asia-Pacific region in pivotal studies, mean that international guidelines cannot be routinely applied to these populations. The Asian Pacific Society of Cardiology developed these consensus recommendations to summarise current evidence on the management of CCS and provide recommendations to assist clinicians treat patients from the region. The consensus recommendations were developed by an expert consensus panel who reviewed and appraised the available literature, with focus on data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting recommendations provide guidance on the assessment and management of bleeding and ischaemic risks in Asian CCS patients. Furthermore, the selection of long-term antithrombotic therapy is discussed, including the role of single antiplatelet therapy, dual antiplatelet therapy and dual pathway inhibition therapy.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: